(Q46921995)

English

Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism

scientific article published on 10 October 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

Cinacalcet treatment decreases plasma fibroblast growth factor 23 concentration in haemodialysed patients with chronic kidney disease and secondary hyperparathyroidism (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

hyperparathyroidism

1 reference

based on heuristic

inferred from title

chronic renal insufficiency

1 reference

based on heuristic

inferred from title

Andrzej Więcek

3

object named as

Andrzej Wiecek

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

Marcin Adamczak

2

object named as

Marcin Adamczak

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

1

object named as

Piotr Kuczera

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

language of work or name

1 reference

based on heuristic

inferred from title

publication date

10 October 2013

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

Clinical Endocrinology

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

80

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

607-612

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

Human fibroblast growth factor-23 mutants suppress Na+-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Fibroblast growth factor 23 in chronic kidney disease: New insights and clinical implications

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Phosphate and Klotho

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Calcium sensing receptor activators: calcimimetics

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients.

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1111%2FCEN.12326

21 January 2018

Identifiers

10.1111/CEN.12326

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/24111496

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46921995&oldid=2137937672"